Ziconotide vs Teduglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Prialt, SNX-111
Ziconotide is a real, FDA-approved painkiller pulled from the venom of a marine cone snail. It is not an opioid, and unlike morphine, people do not build tolerance to it over time. The catch: it only works delivered directly into the spinal fluid through an implanted pump, and its side effect profile is rough enough that it carries a black box warning.
Also: Gattex, Revestive
Teduglutide is a 33-amino-acid GLP-2 analog approved for short bowel syndrome (SBS) in people who depend on IV nutrition or fluids. GLP-2 is the gut's own growth signal, and teduglutide makes the remaining intestine grow taller villi and absorb more, so some patients can cut back the hours they spend hooked to a drip. The FDA approved it as Gattex in December 2012 (children 1 year and older were added in 2019), and in Europe it is sold as Revestive. It works, but it is a serious daily injection with real monitoring requirements, not a gut-health supplement.
Key Comparison Insights
- Both Ziconotide and Teduglutide are FDA approved medications.
- Both peptides belong to the Healing category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Ziconotide | Teduglutide |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Ziconotide is a synthetic copy of omega-conotoxin MVIIA (originally SNX-111), a 25-amino-acid peptide with three disulfide bonds found in the venom of the cone snail Conus magus. It blocks N-type voltage-gated calcium channels, which sit on pain-sensing nerves in the spinal cord's dorsal horn. By shutting those channels, it stops the release of pain-signaling neurotransmitters before the message can travel up to the brain. It barely crosses the blood-brain barrier, which is exactly why it has to be infused intrathecally, straight into the cerebrospinal fluid, to reach its targets. | Teduglutide differs from natural GLP-2 by one amino acid (glycine swapped in at position 2), which shields it from DPP-4 breakdown and stretches its half-life from minutes to roughly 2 hours in healthy people (1.3 hours in SBS). It binds GLP-2 receptors on cells in the intestinal wall, which release local growth factors that increase villus height and crypt depth, improve blood flow to the gut, and slow gastric emptying and secretions. Net result: more absorptive surface and more time to absorb. The same growth signal is the reason for its main safety concern, because it can also speed the growth of polyps or existing tumors in the gut, so the label requires colonoscopy before and during treatment. |
| Common Dosing | Limited community data available See research protocols | 0.05 mg/kg once daily (labeled dose) Once daily |
| Administration | Intrathecal infusion only | Subcutaneous injection, rotating between abdominal quadrants, thighs, or arms |
| Typical Duration | Chronic use via intrathecal pump | Long-term, with assessment of benefit and ongoing monitoring; IV support is weaned as absorption improves |
| Best Time to Take | Morning or as directed | Same time each day, any time of day |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This one is the opposite of speculative. The FDA approved ziconotide as Prialt on December 28, 2004, and the European Commission followed on February 22, 2005. It is indicated for severe chronic pain in patients who need intrathecal therapy and who cannot tolerate or no longer respond to other options, including intrathecal morphine. Its big advantage over opioids is the apparent absence of tolerance or physical dependence even with long-term use. The big problem is a narrow therapeutic window: dizziness, confusion, memory problems, unsteady gait, and serious psychiatric effects including hallucinations and suicidal thoughts, which is why it carries a black box warning and is contraindicated in people with a history of psychosis. Rapid dosing or aggressive dose escalation makes the adverse effects worse, so it is titrated slowly under specialist care. | In the pivotal adult trial (Study 1, NCT00798967), 86 adults with SBS were randomized to teduglutide 0.05 mg/kg daily or placebo for 24 weeks. 63% on teduglutide versus 30% on placebo were responders (at least a 20% cut in weekly IV support at weeks 20 and 24), and weekly IV volume fell 4.4 L versus 2.3 L. In the 2-year open-label extension, 93% of the 30 patients who completed 30 months reached at least a 20% reduction, and a minority came off IV support entirely. An earlier trial (Study 3) used a different primary endpoint that missed at the higher dose, though responder rates at 0.05 mg/kg were 46% versus 6%. A 24-week pediatric study of 59 children aged 1 to 17 led to the 2019 approval: 69% on 0.05 mg/kg cut IV support by at least 20%, and 3 of 26 weaned off. Honest caveats: it is a lifelong therapy for most, benefits fade if stopped, and colon-in-continuity patients often respond less dramatically than those with a stoma. Longer-acting GLP-2 drugs (glepaglutide, apraglutide) are trying to replace the daily shot. |
Frequently Asked Questions: Ziconotide vs Teduglutide
What is the difference between Ziconotide and Teduglutide?
Ziconotide is a healing peptide that ziconotide is a real, fda-approved painkiller pulled from the venom of a marine cone snail. it is not an opioid, and unlike morphine, people do not build tolerance to it over time. the catch: it only works delivered directly into the spinal fluid through an implanted pump, and its side effect profile is rough enough that it carries a black box warning. Teduglutide is a healing peptide that teduglutide is a 33-amino-acid glp-2 analog approved for short bowel syndrome (sbs) in people who depend on iv nutrition or fluids. glp-2 is the gut's own growth signal, and teduglutide makes the remaining intestine grow taller villi and absorb more, so some patients can cut back the hours they spend hooked to a drip. the fda approved it as gattex in december 2012 (children 1 year and older were added in 2019), and in europe it is sold as revestive. it works, but it is a serious daily injection with real monitoring requirements, not a gut-health supplement. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Ziconotide or Teduglutide?
Neither is universally "better" - the choice depends on your specific goals. Ziconotide is typically used for healing purposes, while Teduglutide is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Ziconotide and Teduglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Ziconotide and Teduglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.